Own your ow legal marijuana business | Your guide to making money in the multi-billion dollar marijuana industry |
American Society for Action on Pain |
|
UI - 000008 AU - Hameroff SR TI - Doxepin effects on chronic pain, depression and plasma opioids AB - IN: U Arizona Health Science Ctr, Dept of Anesthesiology, Tucson LA: English AB: Studied 30 26- 65 yr old patients with chronic low back or cervical pain combined with clinical depression in a randomized, double-blind comparison of doxepin and placebo. Dependent variables included Hamilton Rating Scale for Depression (HDRS) scores; the Clinical Global Assessment Scale (CGAS); the Profile of Mood States (POMS); and subjective ratings (visual analog scales) of pain severity, percent of time pain was felt, and effect of pain on activity, muscle tension, sleep, mood, and analgesic consumption. Significant improvements in the doxepin-treated group compared to the placebo group were seen in HDRS, CGAS, and POMS scores; percent of time pain was felt; and effect of pain on sleep, muscle tension, and mood. Some improvement was observed after 1 wk, although most improvement occurred at 6 wks, when the mean doxepin dose was 2.5 mg/kg and plasma doxepin and desmethyldoxepin averaged 70 ng/ml. Nonspecific enkephalinlike activity (but not beta-endorphins) increased for the treatment group and decreased for the placebo group. Doxepin may be a valuable treatment for patients with chronic pain and depression. (12 ref) (PsycLIT Database Copyright 1983 American Psychological Assn, all rights reserved) KP: doxepin; treatment of low back or cervical pain combined with depression; 26-65 yr old patients AN: 69-06286 SO - Journal of Clinical Psychiatry 1982;43:22-27 |